DeepWork Capital — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
Cyrano TherapeuticsinJan 2024 · $9M
Develops regenerative therapy for persistent smell loss, currently in Phase 2 clinical trials.
HealthtechWashington, US
Richard Geoffrion(Executive Officer, Director)Robert Henkin(Director)
BoardGerry Brunk(Director)inTakahide Koda(Director)
Co-investorsRemiges Ventures, Inc.Lumira Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.